search
Back to results

Azithromycin for Preterm Pre-labor Rupture of Membranes

Primary Purpose

Preterm Pre-labor Rupture of Membranes

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Azithromycin
Ampicillin
Azithromycin
Azithromycin
Sponsored by
Assiut University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Preterm Pre-labor Rupture of Membranes

Eligibility Criteria

18 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Gestational age is between 28 wks and 37wks
  2. Singleton living pregnancy.
  3. Confirmed Premature Pre-labor rupture of membranes (PPROM).

Exclusion Criteria:

  1. previable rupture of membranes (<23+6wks)
  2. Multiple gestations
  3. Macrolide allergy
  4. patient receiving combination macrolide therapy
  5. lethal fetal anomalies
  6. contraindications to expectant management of PPROM at time of diagnosis e.g. concurrent preterm labor, placental abruption, chorioamnionitis or non-reassuring fetal testing

Sites / Locations

  • Women Health Hospital - Assiut university

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Azithromycin 1 day group

Azithromycin 5 days group

Arm Description

Patients will receive Azithromycin 1000mg once orally

Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days

Outcomes

Primary Outcome Measures

Days from diagnosis of preterm pre-labor rupture of membranes to delivery.

Secondary Outcome Measures

Full Information

First Posted
December 16, 2019
Last Updated
December 16, 2019
Sponsor
Assiut University
search

1. Study Identification

Unique Protocol Identification Number
NCT04202380
Brief Title
Azithromycin for Preterm Pre-labor Rupture of Membranes
Official Title
Different Azithromycin Protocols for Management of Preterm Pre-labor Rupture of Membranes
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Unknown status
Study Start Date
January 2020 (Anticipated)
Primary Completion Date
January 2021 (Anticipated)
Study Completion Date
March 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Assiut University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The preterm prelabour rupture of membranes is defined as the spontaneous rupture of the fetal membranes before 37 completed weeks. Preterm prelabour rupture of membranes complicates up to 3% of pregnancies and is associated with 30-40% of preterm births. preterm prelabour rupture of membranes can result in significant neonatal morbidity and mortality, primarily from prematurity, sepsis, cord prolapse, and pulmonary hypoplasia. In addition, there are risks associated with chorioamnionitis and placental abruption The diagnosis of spontaneous rupture of the membranes is made by maternal history followed by a sterile speculum examination. If on speculum examination, no amniotic fluid is observed, clinicians should consider performing an insulin-like growth factor-binding protein-1 or placental alpha microglobulin-1 test of vaginal fluid to guide further management. One of the risks associated with preterm prelabour rupture of membranes is ascending infection leading to chorioamnionitis, and subsequent fetal and neonatal infection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Preterm Pre-labor Rupture of Membranes

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Azithromycin 1 day group
Arm Type
Other
Arm Description
Patients will receive Azithromycin 1000mg once orally
Arm Title
Azithromycin 5 days group
Arm Type
Other
Arm Description
Patients will receive Azithromycin 500mg once orally, followed by Azithromycin 250mg orally daily for 4 days
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
Patients will receive Azithromycin orally 1000 mg
Intervention Type
Drug
Intervention Name(s)
Ampicillin
Intervention Description
All patients will receive Ampicillin 2gm IV every 6 hours for 2 days
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
Azithromycin 500 mg orally once
Intervention Type
Drug
Intervention Name(s)
Azithromycin
Intervention Description
Azithromycin 250 mg orally daily for 4 days
Primary Outcome Measure Information:
Title
Days from diagnosis of preterm pre-labor rupture of membranes to delivery.
Time Frame
14 days

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Gestational age is between 28 wks and 37wks Singleton living pregnancy. Confirmed Premature Pre-labor rupture of membranes (PPROM). Exclusion Criteria: previable rupture of membranes (<23+6wks) Multiple gestations Macrolide allergy patient receiving combination macrolide therapy lethal fetal anomalies contraindications to expectant management of PPROM at time of diagnosis e.g. concurrent preterm labor, placental abruption, chorioamnionitis or non-reassuring fetal testing
Facility Information:
Facility Name
Women Health Hospital - Assiut university
City
Assiut
ZIP/Postal Code
71111
Country
Egypt

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Azithromycin for Preterm Pre-labor Rupture of Membranes

We'll reach out to this number within 24 hrs